Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Staar Surgical Co (NASDAQ: STAA) closed at $23.35 down -1.18% from its previous closing price of $23.63. In other words, the price has decreased by -$1.18 from its previous closing price. On the day, 0.67 million shares were traded. STAA stock price reached its highest trading level at $23.7 during the session, while it also had its lowest trading level at $23.31.
Ratios:
For a deeper understanding of Staar Surgical Co’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 5.21. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on April 21, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $17. Mizuho Downgraded its Outperform to Neutral on February 12, 2025, whereas the target price for the stock was revised from $45 to $17.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 21 ’25 when BROADWOOD PARTNERS, L.P. bought 797,486 shares for $27.86 per share. The transaction valued at 22,218,837 led to the insider holds 15,019,491 shares of the business.
BROADWOOD PARTNERS, L.P. bought 393,382 shares of STAA for $10,675,325 on Nov 20 ’25. The 10% Owner now owns 14,222,005 shares after completing the transaction at $27.14 per share. On Nov 19 ’25, another insider, BROADWOOD PARTNERS, L.P., who serves as the 10% Owner of the company, bought 309,132 shares for $26.42 each. As a result, the insider paid 8,166,155 and bolstered with 13,828,623 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STAA now has a Market Capitalization of 1152695040 and an Enterprise Value of 1007931584. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.04 while its Price-to-Book (P/B) ratio in mrq is 3.26. Its current Enterprise Value per Revenue stands at 4.371 whereas that against EBITDA is -18.668.
Stock Price History:
The Beta on a monthly basis for STAA is 0.99, which has changed by -0.030315638 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, STAA has reached a high of $30.81, while it has fallen to a 52-week low of $13.50. The 50-Day Moving Average of the stock is -9.15%, while the 200-Day Moving Average is calculated to be 5.45%.
Shares Statistics:
For the past three months, STAA has traded an average of 1.17M shares per day and 1500270 over the past ten days. A total of 49.35M shares are outstanding, with a floating share count of 49.34M. Insiders hold about 0.81% of the company’s shares, while institutions hold 106.04% stake in the company. Shares short for STAA as of 1765756800 were 4826529 with a Short Ratio of 4.13, compared to 1763078400 on 3662036. Therefore, it implies a Short% of Shares Outstanding of 4826529 and a Short% of Float of 17.06.
Earnings Estimates
A comprehensive evaluation of Staar Surgical Co (STAA) is underway, with the input of 5.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.03, with high estimates of $0.13 and low estimates of -$0.21.
Analysts are recommending an EPS of between $0.14 and -$0.06 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is $0.37, with 6.0 analysts recommending between $0.78 and -$0.23.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $75.55M this quarter.It ranges from a high estimate of $78.3M to a low estimate of $72.98M. As of. The current estimate, Staar Surgical Co’s year-ago sales were $48.95MFor the next quarter, 6 analysts are estimating revenue of $71.99M. There is a high estimate of $79.1M for the next quarter, whereas the lowest estimate is $60.7M.
A total of 7 analysts have provided revenue estimates for STAA’s current fiscal year. The highest revenue estimate was $259.9M, while the lowest revenue estimate was $254.6M, resulting in an average revenue estimate of $257.23M. In the same quarter a year ago, actual revenue was $313.9MBased on 10 analysts’ estimates, the company’s revenue will be $314.5M in the next fiscal year. The high estimate is $344.5M and the low estimate is $271M.
